Skip to content
DataLookout
Menu

SHIPSSNCT03401398

Stress Hydrocortisone In Pediatric Septic Shock

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 61 versions: 48 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 5 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Site details revised at 44 of 44 sites
    • Collaborators: details revised at 1 of 4 entries
    • Publications: details revised at 3 of 3 entries
  2. Minor Site details revised at 2 of 44 sitesv60
  3. Minor Study sites: 51 to 44v59
  4. Minor Site details revised at 4 of 51 sitesv58
  5. Minor Site contacts updated at 1 of 51 sites
    • Study description shortened, about 1 word
    v57
Show 43 earlier versionsHide 43 earlier versions
  1. Minor Study sites: 52 to 51v56
  2. Minor Study sites: 51 to 52v55
  3. Notable Eligibility criteria expanded, about 33 words
    • Study sites: 44 to 51
    • Study description revised
    v54
  4. Notable Enrollment target: 1032 to 500
    • Study sites: 46 to 44
    v53
  5. Notable Primary completion date: Sep 30, 2025 to Sep 30, 2026v52 Show 5 more changesShow less
    • Primary endpoint revised
    • Study completion date: Dec 21, 2025 to Dec 31, 2026
    • Secondary endpoint revised
    • Study description expanded, about 6 words
    • Site details revised at 2 of 46 sites
  6. Minor Study description expanded, about 13 wordsv51
  7. Minor Site details revised at 1 of 46 sitesv50
  8. Notable Eligibility criteria expanded, about 6 words
    • Study sites revised (46)
    v49
  9. Minor Study sites: 45 to 46v48
  10. Minor Site details revised at 1 of 45 sitesv47
  11. Minor Primary completion date: Jun 30, 2025 to Sep 30, 2025
    • Study completion date: Sep 30, 2025 to Dec 21, 2025
    v46
  12. Minor Study sites: 34 to 45v45
  13. Minor Study sites: 32 to 34v44
  14. Minor Site contacts updated at 1 of 32 sitesv43
  15. Minor Site contacts updated at 1 of 32 sitesv42
  16. Notable Primary completion date: Sep 20, 2024 to Jun 30, 2025
    • Study completion date: Dec 30, 2024 to Sep 30, 2025
    • Site details revised at 1 of 32 sites
    v41
  17. Notable Primary completion date: Sep 20, 2023 to Sep 20, 2024
    • Eligibility criteria expanded, about 3 words
    • Study sites: 33 to 32
    • Study completion date: Dec 30, 2023 to Dec 30, 2024
    v40
  18. Minor Site details revised at 2 of 33 sitesv39
  19. Minor Site details revised at 1 of 33 sitesv38
  20. Minor Study sites: 30 to 33v37
  21. Minor Study sites: 29 to 30v36
  22. Minor Site details revised at 1 of 29 sitesv35
  23. Minor Site details revised at 1 of 29 sitesv34
  24. Minor Site details revised at 1 of 29 sitesv33
  25. Minor Site details revised at 1 of 29 sitesv32
  26. Minor Site details revised at 3 of 29 sitesv31
  27. Minor Study sites revised (29)v30
  28. Notable Eligibility criteria expanded, about 27 words
    • Study sites: 30 to 29
    v29
  29. Minor Site details revised at 1 of 30 sitesv28
  30. Minor Site details revised at 1 of 30 sitesv27
  31. Minor Site details revised at 2 of 30 sitesv26
  32. Minor Site details revised at 2 of 30 sitesv25
  33. Minor Site details revised at 2 of 30 sitesv24
  34. Minor Study sites: 32 to 30v23
  35. Minor Study sites: 31 to 32v22
  36. Minor Site details revised at 3 of 31 sitesv21
  37. Notable Trial status: Suspended to Recruiting
    • Site details revised at 31 of 31 sites
    v20
  38. Stopped Trial status: Recruiting to Suspended Sponsor's reason: All sites have been put on hold due to the ongoing COVID-19 pandemic
    • Site details revised at 31 of 31 sites
    v17
  39. Minor Site details revised at 1 of 31 sitesv16
  40. Minor Site details revised at 1 of 31 sitesv15
  41. Notable Eligibility criteria shortened, about 3 words
    • Study description shortened, about 2 words
    v14
  42. Minor Site details revised at 1 of 31 sitesv13
  43. Minor Site details revised at 1 of 31 sitesv12
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

New or progressive multiple organ dysfunction syndrome as assessed utilizing the Pediatric Logistic Organ Dysfunction (PELOD-2) instrument.
Timeframe: 28 days following study enrollment

Secondary (1)

28-day hospital mortality or ≥25% decrease from baseline in health-related quality of life (HRQL) assessed utilizing the Pediatric Quality of Life Inventory, (PedsQL)

Arms and interventions

TreatmentActive comparator

Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.

PlaceboPlacebo comparator

Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.

Drugs: Hydrocortisone, sodium succinate, Normal saline

Sites

44 sites in 10 countries

United States 18, Canada 10, Israel 3, Malaysia 3, Brazil 2, Japan 2, Pakistan 2, Vietnam 2, Saudi Arabia 1, Singapore 1